When it comes to genome editing, CRISPR is undeniably king. But these molecular scissors aren’t the only tools used to rejigger genetic material. Previous generations of gene-editing tools are still very much in play — particularly zinc finger nucleases, TALEN, and meganucleases. And there’s a bit of a misconception that the prior generations are inferior to CRISPR technology: In reality, they may offer some advantages.

“I would say that zinc finger nucleases, TALEN, and meganucleases all work well and can be as active and specific as CRISPR,” said Dr. Donald Kohn, director of the human gene medicine program at University of California, Los Angeles. The major advantage of CRISPR, he said, is that it’s far easier to design — “whereas the other nucleases require more extensive development to make them more effective.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy